Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur, the vaccines division of the Sanofi-Aventis, has announced that the FDA has licensed Daptacel to be administered as a fifth consecutive diphtheria, tetanus, and acellular pertussis vaccine dose for children four years through six years of age.
Subscribe to our email newsletter
The approval of the fifth consecutive dose of Daptacel vaccine completes the FDA license for the entire five-dose Daptacel vaccine series enabling health-care professionals to administer the same brand of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine for the series as recommended by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP).
The fifth consecutive dose of Daptacel vaccine also provides a convenient fit with the CDC’s recommended immunization schedule. According to the ACIP, AAP, and AAFP recommendations, these five doses should be administered before seven years of age.